Qian Zeng1, Meiqin Liu2, Na Zhou1, Lisheng Liu2, Xianrang Song3. 1. Clinical laboratory of Shandong Cancer Hospital & Institute, PR China; School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medicine Science, PR China. 2. Clinical laboratory of Shandong Cancer Hospital & Institute, PR China. 3. Clinical laboratory of Shandong Cancer Hospital & Institute, PR China. Electronic address: sxr@vip.163.com.
Abstract
BACKGROUND: Human epididymis protein 4 (HE4) had been shown to be an ideal biomarker in ovarian cancer. However, there were fewer reports on its application in lung cancer. We explored the diagnostic value of serum HE4 as a biomarker in early lung cancer by comparing it with other biomarkers. METHODS: 162 individuals including 112 cases of lung cancer at early stage and 50 healthy people as controls were enrolled. The serum concentrations of biomarkers were determined with the Roche Elecsys assays. RESULTS: In comparison to the other biomarkers such as carcinoembryonic antigen (CEA), neuron-specific-enolase (NSE), serum cytokeratin 19 fragment (CYFRA 21-1) and progastrinreleasing peptide (proGRP), serum HE4 was one of the biomarkers with the highest sensitivity (43.8%) and specificity (95.0%) for early lung cancer diagnosis. In terms of histological results, serum HE4 was the best biomarker both in adenocarcinoma (AC) and squamous carcinoma (SC), and serum proGRP was the best in small cell lung cancer (SCLC). The combination of proGRP, NSE and HE4 could determine the histological type of lung cancer with a very high accuracy of 93.8%. CONCLUSIONS: These findings suggested that serum HE4 was a better biomarker in early lung cancer than other frequently-used biomarkers.
BACKGROUND:Humanepididymis protein 4 (HE4) had been shown to be an ideal biomarker in ovarian cancer. However, there were fewer reports on its application in lung cancer. We explored the diagnostic value of serum HE4 as a biomarker in early lung cancer by comparing it with other biomarkers. METHODS: 162 individuals including 112 cases of lung cancer at early stage and 50 healthy people as controls were enrolled. The serum concentrations of biomarkers were determined with the Roche Elecsys assays. RESULTS: In comparison to the other biomarkers such as carcinoembryonic antigen (CEA), neuron-specific-enolase (NSE), serum cytokeratin 19 fragment (CYFRA 21-1) and progastrinreleasing peptide (proGRP), serum HE4 was one of the biomarkers with the highest sensitivity (43.8%) and specificity (95.0%) for early lung cancer diagnosis. In terms of histological results, serum HE4 was the best biomarker both in adenocarcinoma (AC) and squamous carcinoma (SC), and serum proGRP was the best in small cell lung cancer (SCLC). The combination of proGRP, NSE and HE4 could determine the histological type of lung cancer with a very high accuracy of 93.8%. CONCLUSIONS: These findings suggested that serum HE4 was a better biomarker in early lung cancer than other frequently-used biomarkers.
Authors: Chanhee Han; Stefania Bellone; Eric R Siegel; Gary Altwerger; Gulden Menderes; Elena Bonazzoli; Tomomi Egawa-Takata; Francesca Pettinella; Anna Bianchi; Francesco Riccio; Luca Zammataro; Ghanshyam Yadav; Jarrod A Marto; Marie-France Penet; Douglas A Levine; Ronny Drapkin; Abhijit Patel; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Alessandro D Santin Journal: Gynecol Oncol Date: 2018-03-21 Impact factor: 5.482
Authors: Florence Guida; Nan Sun; Leonidas E Bantis; David C Muller; Peng Li; Ayumu Taguchi; Dilsher Dhillon; Deepali L Kundnani; Nikul J Patel; Qingxiang Yan; Graham Byrnes; Karel G M Moons; Anne Tjønneland; Salvatore Panico; Claudia Agnoli; Paolo Vineis; Domenico Palli; Bas Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Jose M Huerta; Miren Dorronsoro; Miguel Rodriguez Barranco; Eva Ardanaz; Ruth C Travis; Karl Smith Byrne; Heiner Boeing; Annika Steffen; Rudolf Kaaks; Anika Hüsing; Antonia Trichopoulou; Pagona Lagiou; Carlo La Vecchia; Gianluca Severi; Marie-Christine Boutron-Ruault; Torkjel M Sandanger; Elisabete Weiderpass; Therese H Nøst; Kostas Tsilidis; Elio Riboli; Kjell Grankvist; Mikael Johansson; Gary E Goodman; Ziding Feng; Paul Brennan; Mattias Johansson; Samir M Hanash Journal: JAMA Oncol Date: 2018-10-11 Impact factor: 31.777